In these videos, Dr Ilan Melnick, Chief Medical Officer at Passageway Residences of Miami-Dade County, discusses the impact of agitation associated with Alzheimer’s dementia and the benefits of treatment with REXULTI.
PBS Information: Authority Required (STREAMLINED) for the treatment of schizophrenia. Code: 4246. This product is not listed on the PBS for the treatment of agitation associated with Alzheimer's dementia.
Please review Approved Product Information before prescribing.
Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:
REXULTI® is a registered trademark of H. Lundbeck A/S. REXULTI® is co-commercialised by Lundbeck Australia Pty Ltd and Otsuka Australia Pharmaceutical Pty Limited.
